Clinical features of heparin-induced thrombocytopenia including risk factors for thrombosis. A retrospective analysis of 408 patients.
about
Heparin-induced thrombocytopenia in the ICU: an overviewVenous thromboembolic diseaseHeparin-induced thrombocytopenia in solid organ transplant recipients: The current scientific knowledgeA 56-Day Oral Toxicity Study of the Aqueous Extract of Rapanea melanophloeos (L.) Mez in RatsMonocyte-bound PF4 in the pathogenesis of heparin-induced thrombocytopenia.Endothelial antigen assembly leads to thrombotic complications in heparin-induced thrombocytopeniaMassive Pulmonary Embolism in a Patient with Heparin Induced Thrombocytopenia: Successful Treatment with Dabigatran.Severe heparin-induced thrombocytopenia: when the obvious is not obvious, a case report.Optimization of a murine immunization model for study of PF4/heparin antibodies.Validation of the high-dose heparin confirmatory step for the diagnosis of heparin-induced thrombocytopenia.PRT-060318, a novel Syk inhibitor, prevents heparin-induced thrombocytopenia and thrombosis in a transgenic mouse model.CalDAG-GEFI deficiency protects mice in a novel model of Fcγ RIIA-mediated thrombosis and thrombocytopenia.Treatment and prevention of heparin-induced thrombocytopenia: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.The Pharmacotherapy of Heparin-Induced Thrombocytopenia (HIT) : A Review of Contemporary Therapeutic Challenges in Clinical Practice.Emphasis on the Role of PF4 in the Incidence, Pathophysiology and Treatment of Heparin Induced Thrombocytopenia.Recent advances in the diagnosis and treatment of heparin-induced thrombocytopenia.Distinct specificity and single-molecule kinetics characterize the interaction of pathogenic and non-pathogenic antibodies against platelet factor 4-heparin complexes with platelet factor 4.Bilateral adrenal haemorrhage associated with heparin-induced thrombocytopaenia during treatment of Fournier gangrene.Heparin-independent, PF4-dependent binding of HIT antibodies to platelets: implications for HIT pathogenesis.Pediatric heparin-induced thrombocytopenia: prevalence, thrombotic risk, and application of the 4Ts scoring systemA genome-wide association study of heparin-induced thrombocytopenia using an electronic medical record.Platelet transfusions in platelet consumptive disorders are associated with arterial thrombosis and in-hospital mortality.Safety and economic considerations of argatroban use in critically ill patients: a retrospective analysisIs the incidence trend of heparin-induced thrombocytopenia decreased by the increased use of low-molecular-weight-heparin?Platelet transactivation by monocytes promotes thrombosis in heparin-induced thrombocytopenia.Heparin-Induced Thrombocytopenia in Cardiac Surgery Patients.Influence of human leukocyte antigen (HLA) alleles and killer cell immunoglobulin-like receptors (KIR) types on heparin-induced thrombocytopenia (HIT).
P2860
Q21194907-3D95E08A-FC14-4E31-9029-C18A2DEA5851Q24631121-E5B2CD01-9276-40D0-A7AC-BF937995C505Q26751442-AE9A4F45-CE0A-4BBA-9ED9-909285D62CA4Q28468384-86B40FF1-85E8-4185-B0C5-7EB8C8739726Q30497774-882AC086-CB5C-48AF-840E-23DF14531159Q30840169-C074E6E3-7F7E-4B70-87AA-D71686A50E7DQ33166993-B6CA1A36-1B00-4098-AB34-7156A66FDC23Q33375082-CA79EDE4-2A69-4BBF-8406-8A92ACC2D0AEQ33383456-3060C90D-6015-4B2A-8CD8-961328A58131Q33389839-C78960D3-766F-454E-8554-2849DC3F1338Q33392880-A4F2F805-1CDF-486E-9ABA-E79868C9199BQ33395687-9C7EFBD3-D127-4662-83DB-03C9B8071DF0Q33399580-76CF5869-CDFD-408D-A9FF-51F9EF4018C3Q33401236-001AC157-E7C8-48F1-AB3D-33C00E5FF395Q33406904-72666E69-456E-4D75-8CBB-7A88E67586A2Q33407198-CA1AFE51-DF27-40A4-A885-21F9A540A43BQ33410765-4300F0AE-BDD8-4845-B64C-F1DF8CCBA3F9Q33418205-9B47D1FB-09C4-40B8-80DA-F888D457B426Q33418371-671304C0-DC82-4D72-BA90-D910314D1E98Q33418994-428FF8CB-8ED8-4FF6-A61D-9A749D422291Q33419319-A23374CF-99AE-4E3C-A412-E6DB522DF734Q33419774-1239EBB4-1002-4B5F-8C69-D3FE702D114BQ33422064-5CA64020-C809-4D0E-9902-3E71C8F57F5EQ33422736-EC125F67-4680-4C3F-9FBC-1E8155A6400FQ33427182-E7F64B18-122C-45E8-A926-6657E88EA93EQ33442571-A0A07834-6BC2-4137-9812-B1986208AB8AQ33443448-BD8DE635-ECA2-424A-96FC-C5F54EEFFB48
P2860
Clinical features of heparin-induced thrombocytopenia including risk factors for thrombosis. A retrospective analysis of 408 patients.
description
2005 nî lūn-bûn
@nan
2005 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Clinical features of heparin-i ...... tive analysis of 408 patients.
@ast
Clinical features of heparin-i ...... tive analysis of 408 patients.
@en
type
label
Clinical features of heparin-i ...... tive analysis of 408 patients.
@ast
Clinical features of heparin-i ...... tive analysis of 408 patients.
@en
prefLabel
Clinical features of heparin-i ...... tive analysis of 408 patients.
@ast
Clinical features of heparin-i ...... tive analysis of 408 patients.
@en
P2093
P356
P1476
Clinical features of heparin-i ...... tive analysis of 408 patients.
@en
P2093
Beate Farner
Hartmut Kroll
Petra Eichler
Thomas Kohlmann
P304
P356
10.1267/THRO05010132
P577
2005-07-01T00:00:00Z